Comparison 1. Transfusion‐dependent thalassemia: deferasirox vs placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality at any time point	2	47	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 AEs	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
2.1 Eye disorders ‐ retinal infarct	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.2 GI disorders ‐ abdominal pain	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.3 GI disorders ‐ diarrhoea	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.4 GI disorders ‐ nausea	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.5 Investigations ‐ extended QT interval, hypocalcaemia, hypoparathyroidism	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.6 Skin and subcutaneous tissue disorders ‐ rash	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3 Discontinuations due to serious AEs	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected